Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 307, Issue 1, 2014, Pages

  Favia, Maria ^a   Mancini, Maria T ^a   Bezzerri, Valentino ^b   Guerra, Lorenzo ^a   Laselva, Onofrio ^a   Abbattiscianni, Anna C ^a   Debellis, Lucantonio ^a   Reshkin, Stephan J ^a   Gambari, Roberto ^c   Cabrini, Giulio ^b   Casavola, Valeria ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Chloride transport; Cystic fibrosis; F508del cystic fibrosis transmembrane conductance regulator corrector; F508del cystic fibrosis transmembrane conductance regulator rescue

Indexed keywords

ANGELICIN; ANTIINFLAMMATORY AGENT; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; TRIMETHYLANGELICIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APICAL MEMBRANE; ARTICLE; CELL SURFACE; CHLORIDE TRANSPORT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS AIRWAY CELL; DENSITOMETRY; DOSE RESPONSE; ENDOCYTOSIS; EPITHELIUM CELL; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LUNG ALVEOLUS CELL; LUNG FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; WESTERN BLOTTING;

CHLORIDE TRANSPORT; CYSTIC FIBROSIS; F508DEL CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CORRECTOR; F508DEL CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR RESCUE;

ANIMALS; CELL LINE; CELL MEMBRANE; CHLORIDES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC RETICULUM; HEK293 CELLS; HUMANS; LUNG; PROTEIN TRANSPORT; PSORALENS; RATS;

EID: 84903649442     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00305.2013     Document Type: Article

References (73)

1. Amaral MD, Farinha CM. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr Pharm Des 19: 3497-3508, 2013.
2. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S. Determination that CFTR is a chloride channel by alteration of its anion selectivity. Science 253: 202-205, 1991.
3. Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 3, 2011.
4. Bebok Z, Collawn JF, Wakefield J, Parker W, Li Y, Varga K, Sorscher EJ, Clancy JP. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o-airway epithelial monolayers. J Physiol 569: 601-615, 2005.
5. Bebok Z, Venglarik CJ, Panczel Z, Jilling T, Kirk KL, Sorscher EJ. Activation of deltaF508 CFTR in an epithelial monolayer. Am J Physiol Cell Physiol 275: C599-C607, 1998.
6. Berger AL, Ikuma M, Welsh MJ. Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. Proc Natl Acad Sci USA 102: 455-460, 2005.
7. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 13: 231-240, 2007.
8. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261: 5-16, 2007.
9. Cai Z, Taddei A, Sheppard DN. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Clchannel. J Biol Chem 281: 1970-1977, 2006.
10. Carlile GW, Robert R, Zhang D, Teske KA, Luo Y, Hanrahan JW, Thomas DY. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 8: 1012-1020, 2007.
11. Cheng SH, Rich DP, Marshall J, Gregory RJ, Welsh MJ, Smith AE. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66: 1027-1036, 1991.
12. Cholon DM, O'Neal WK, Randell SH, Riordan JR, Gentzsch M. Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol 298: L304-L314, 2010.
13. Csanady L, Vergani P, Gadsby DC. Strict coupling between CFTR's catalytic cycle and gating of its Cl-ion pore revealed by distributions of open channel burst durations. Proc Natl Acad Sci USA 107: 1241-1246, 2010.
14. Dannhoffer L, Billet A, Jollivet M, Melin-Heschel P, Faveau C, Becq F. Stimulation of wild-type, F508del-and G551D-CFTR chloride channels by non-toxic modified pyrrolo[2,3-b]pyrazine derivatives (Abstract). Front Pharmacol 2: 48, 2011.
15. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764, 1992.
16. Du K, Sharma M, Lukacs GL. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12: 17-25, 2005.
17. Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 287: 36639-36649, 2012.
18. + exchanger regulatory factor 1 overexpression-dependent increase of cytoskeleton organization is fundamental in the rescue of F508del cystic fibrosis transmembrane conductance regulator in human airway CFBE41o-cells. Mol Biol Cell 21: 73-86, 2010.
19. Ficker E, Dennis AT, Wang L, Brown AM. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92: e87-e100, 2003.
20. + exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o-cells and rescues DeltaF508 CFTR functional expression in cystic fibrosis cells. J Biol Chem 280: 40925-40933, 2005.
21. Hanrahan JW, Sampson HM, Thomas DY. Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci 34: 119-125, 2013.
22. Heda GD, Tanwani M, Marino CR. The Delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 280: C166-C174, 2001.
23. Holleran JP, Glover ML, Peters KW, Bertrand CA, Watkins SC, Jarvik JW, Frizzell RA. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol Med 18: 685-696, 2012.
24. Huang P, Gilmore E, Kultgen P, Barnes P, Milgram S, Stutts MJ. Local regulation of cystic fibrosis transmembrane regulator and epithelial sodium channel in airway epithelium. Proc Am Thorac Soc 1: 33-37, 2004.
25. Hwang TC, Sheppard DN. Gating of the CFTR Cl-channel by ATPdriven nucleotide-binding domain dimerisation. J Physiol 587: 2151-2161, 2009.
26. Illek B, Fischer H, Santos GF, Widdicombe JH, Machen TE, Reenstra WW. cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol Cell Physiol 268: C886-C893, 1995.
27. Jurkuvenaite A, Chen L, Bartoszewski R, Goldstein R, Bebok Z, Matalon S, Collawn JF. Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 42: 363-372, 2010.
28. Jurkuvenaite A, Varga K, Nowotarski K, Kirk KL, Sorscher EJ, Li Y, Clancy JP, Bebok Z, Collawn JF. Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis. J Biol Chem 281: 3329-3334, 2006.
29. Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, Ben-Zeev E, Schutz N, Pedemonte N, Thomas PJ, Bridges RJ, Wetmore DR, Marantz Y, Senderowitz H. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 24: 971-991, 2010.
30. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151: 1075-1082, 1995.
31. Kim SJ, Skach WR. Mechanisms of CFTR folding at the endoplasmic reticulum (Abstract). Front Pharmacol 3: 201, 2012.
32. Knapp JM, Wood AB, Phuan PW, Lodewyk MW, Tantillo DJ, Verkman AS, Kurth MJ. Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in DeltaF508 cystic fibrosis transmembrane conductance regulator protein. J Med Chem 55: 1242-1251, 2012.
33. Lewis HA, Wang C, Zhao X, Hamuro Y, Conners K, Kearins MC, Lu F, Sauder JM, Molnar KS, Coales SJ, Maloney PC, Guggino WB, Wetmore DR, Weber PC, Hunt JF. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J Mol Biol 396: 406-430, 2010.
34. Li C, Naren AP. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol Ther 108: 208-223, 2005.
35. Lin H, Li H, Cho HJ, Bian S, Roh HJ, Lee MK, Kim JS, Chung SJ, Shim CK, Kim DD. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sci 96: 341-350, 2007.
36. Loo TW, Bartlett MC, Clarke DM. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 413: 29-36, 2008.
37. Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR, Grinstein S. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 268: 21592-21598, 1993.
38. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658, 2002.
39. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR, 3rd Segatori L, Kelly JW. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134: 769-781, 2008.
40. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J, Young JC, Lukacs GL. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329: 805-810, 2010.
41. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, Hegedus T, Beekman JM, Lukacs GL. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 9: 444-454, 2013.
42. Ostedgaard LS, Zeiher B, Welsh MJ. Processing of CFTR bearing the P574H mutation differs from wild-type and deltaF508-CFTR. J Cell Sci 112: 2091-2098, 1999.
43. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJV, Verkman AS. Small-molecule correctors of defective DF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564-2571, 2005.
44. Pedemonte N, Tomati V, Sondo E, Caci E, Millo E, Armirotti A, Damonte G, Zegarra-Moran O, Galietta LJ. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J Biol Chem 286: 15215-15226, 2011.
45. Pedemonte N, Tomati V, Sondo E, Galietta LJ. Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298: C866-C874, 2010.
46. Phuan PW, Yang B, Knapp JM, Wood AB, Lukacs GL, Kurth MJ, Verkman AS. Cyanoquinolines with independent corrector and potentiator activities restore DeltaPhe508-cystic fibrosis transmembrane conduc-tance regulator chloride channel function in cystic fibrosis. Mol Pharmacol 80: 683-693, 2011.
47. Puchelle E, De Bentzmann S, Hubeau C, Jacquot J, Gaillard D. Mechanisms involved in cystic fibrosis airway inflammation. Pediatr Pulmonol Suppl 23: 143-145, 2001.
48. Ramsey BW, Banks-Schlegel S, Accurso FJ, Boucher RC, Cutting GR, Engelhardt JF, Guggino WB, Karp CL, Knowles MR, Kolls JK, LiPuma JJ, Lynch S, McCray PB Jr, Rubenstein RC, Singh PK, Sorscher E, Welsh M. Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report. Am J Respir Crit Care Med 185: 887-892, 2012.
49. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726, 2008.
50. Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas DY, Hanrahan JW. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 73: 478-489, 2008.
51. Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23: 268-278, 2010.
52. Sampson HM, Robert R, Liao J, Matthes E, Carlile GW, Hanrahan JW, Thomas DY. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 18: 231-242, 2011.
53. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271: 635-638, 1996.
54. Sharma M, Benharouga M, Hu W, Lukacs GL. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem 276: 8942-8950, 2001.
55. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, Bache KG, Papsin B, Zerangue N, Stenmark H, Lukacs GL. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 164: 923-933, 2004.
56. Sondo E, Tomati V, Caci E, Esposito AI, Pfeffer U, Pedemonte N, Galietta LJ. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol 301: C872-C885, 2011.
57. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ. Altered channel gating mechanism for CFTR inhibition by a highaffinity thiazolidinone blocker. FEBS Lett 558: 52-56, 2004.
58. Tamanini A, Borgatti M, Finotti A, Piccagli L, Bezzerri V, Favia M, Guerra L, Lampronti I, Bianchi N, Dall'acqua F, Vedaldi D, Salvador A, Fabbri E, Mancini I, Nicolis E, Casavola V, Cabrini G, Gambari R. Trimethylangelicin Reduces IL-8 Transcription and Potentiates CFTR Function. Am J Physiol Lung Cell Mol Physiol 300: L380-L390, 2011.
59. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106: 18825-18830, 2009.
60. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108: 18843-18848, 2011.
61. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117-L1130, 2006.
62. Varga K, Goldstein RF, Jurkuvenaite A, Chen L, Matalon S, Sorscher EJ, Bebok Z, Collawn JF. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 410: 555-564, 2008.
63. Veit G, Bossard F, Goepp J, Verkman AS, Galietta LJ, Hanrahan JW, Lukacs GL. Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol Biol Cell 23: 4188-4202, 2012.
64. Vergani P, Lockless SW, Nairn AC, Gadsby DC. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433: 876-880, 2005.
65. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 8: 153-171, 2009.
66. Verkman AS, Lukacs GL, Galietta LJ. CFTR chloride channel drug discovery-inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des 12: 2235-2247, 2006.
67. Wang Y, Bartlett MC, Loo TW, Clarke DM. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70: 297-302, 2006.
68. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem 282: 33247-33251, 2007.
69. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitinproteasome pathway. Cell 83: 121-127, 1995.
70. Yu W, Kim Chiaw P, Bear CE. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant. J Biol Chem 286: 24714-24725, 2011.
71. Zabner J, Karp P, Seiler M, Phillips SL, Mitchell CJ, Saavedra M, Welsh M, Klingelhutz AJ. Development of cystic fibrosis and noncystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 284: L844-L854, 2003.
72. Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, Dang YL, Vogel LN, McKay T, Mengos A, Boucher RC, Collins PL, Pickles RJ. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 7: e1000155, 2009.
73. Zhang XM, Wang XT, Yue H, Leung SW, Thibodeau PH, Thomas PJ, Guggino SE. Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. J Biol Chem 278: 51232-51242, 2003.